What question did this study set out to answer?

Correct an erroneous drug indication published in a summary table reviewing cancer drug approvals over a five-year period.

April 2, 2015JAMA OncologyOpen Access

Five Years of Cancer Drug Approvals

View Full Paper

Ask AI

Bookmark

Authors

SMSham MailankodyMemorial Sloan Kettering Cancer Center VPVinay PrasadNationwide Children's Hospital

Discussion

Member takes

Implication

Correction report demonstrates the verified clinical indication for ibrutinib in mantle cell lymphoma, highlighting accurate oncology drug approval records.

Key Points

Correct an erroneous drug indication published in a summary table reviewing cancer drug approvals over a five-year period.
Issued an erratum to revise mislabeled clinical indication details within the published cancer drug approval table.
Corrected the indication for ibrutinib to mantle cell lymphoma, resolving an error in the original published table.

Cite This Study

Mailankody et al. (2015) studied this question.

synapsesocial.com/papers/6a6f563da528af2d65c2f113 https://doi.org/10.1001/jamaoncol.2015.0373

View Full Paper

Ask AI

Bookmark

Implication

Correction report demonstrates the verified clinical indication for ibrutinib in mantle cell lymphoma, highlighting accurate oncology drug approval records.

Five Years of Cancer Drug Approvals

Discussion

Member takes

Implication

Key Points

Cite This Study

Five Years of Cancer Drug Approvals

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider